Stock of the Day

November 10, 2023

STAAR Surgical (STAA)

$23.40
+$0.81 (+3.6%)
Market Cap: $1.17B

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Today's Trend

STAAR Surgical Company (NASDAQ: STAA) shares have decreased as investors weighed strong second-quarter growth and profitability against an earnings miss versus some analyst estimates and execution risks related to its China supply-chain transition.

  • STAAR Surgical reported robust second-quarter 2026 results, including revenue of approximately $93.5 million, up more than 100% year over year. Earnings were positive and exceeded at least one consensus estimate, with Zacks reporting adjusted EPS of $0.31 versus expectations of $0.21. STAAR Surgical Surpasses Q2 Earnings and Revenue Estimates
  • Management highlighted strong procedure demand and continued growth in its implantable collamer lens business. The company also expects to finish 2026 with well over $200 million in cash, supporting financial flexibility and reducing balance-sheet risk. STAAR Surgical Cash and China Supply Update
  • Wedbush maintained an “outperform” rating, although it reduced its price target from $40 to $37. The revised target still implies substantial upside from the stock’s recent level, offering a degree of analyst support. Wedbush Price Target Update
  • STAAR plans to shift 100% of its China supply to Switzerland. The move may improve supply-chain control and resilience over time, but investors could remain focused on the cost, timing and execution of the transition. STAAR Surgical China Supply Transition
  • Reported EPS figures differed by source, but one widely cited release showed $0.16 per share versus a $0.22 analyst consensus, creating an earnings miss despite revenue of $93.53 million exceeding the $90.60 million estimate. That mixed results profile likely contributed to selling pressure. STAAR Surgical Quarterly Earnings Report
← Previous Stock of the DayNext Stock of the Day →

Recent News